Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Workiva Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Workiva Inc trades at $72.22 (market cap $3.95B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Workiva Inc is more actively traded (612,757 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Workiva Inc for 20 Days on average.
| SYRE | WK | |
|---|---|---|
Market Cap | $7.52B | $3.95B |
Volume | 1,441,031 | 612,757 |
Sector | Health | Technology |
52-Week High | $108.92 | $93.31 |
52-Week Low | $22.18 | $44.31 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $6.52B | $3.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
WK trades at $72.50, down 0.74% on the day, with strong technical momentum showing bullish moving averages and support at $72. The company demonstrates robust revenue growth, reaching $966M in 2026 with net income turning positive at $47M, while consistently beating earnings expectations. Recent product innovations in AI and regulatory technology highlight ongoing business development.
The outlook remains positive with 89% analyst buy ratings and an $86 price target, though elevated valuation multiples and execution risks in competitive markets warrant caution. Upside potential exists if earnings growth continues, but investors should monitor margin sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
